Optimization of Processing Parameters of Nanoemulsion Containing Aripiprazole Using Response Surface Methodology.
APD
PKOES
RSM
antipsychotic drug
aripiprazole
nanoemulsion
palm kernel oil esters
response surface methodology
schizophrenia
Journal
International journal of nanomedicine
ISSN: 1178-2013
Titre abrégé: Int J Nanomedicine
Pays: New Zealand
ID NLM: 101263847
Informations de publication
Date de publication:
2020
2020
Historique:
received:
19
12
2018
accepted:
12
11
2019
entrez:
27
3
2020
pubmed:
27
3
2020
medline:
3
7
2020
Statut:
epublish
Résumé
Aripiprazole, which is a quinolinone derivative, has been widely used to treat schizophrenia, major depressive disorder, and bipolar disorder. A Central Composite Rotatable Design (CCRD) of Response Surface Methodology (RSM) was used purposely to optimize process parameters conditions for formulating nanoemulsion containing aripiprazole using high emulsification methods. This design is used to investigate the influences of four independent variables (overhead stirring time (A), shear rate (B), shear time (C), and the cycle of high-pressure homogenizer (D)) on the response variable namely, a droplet size (Y) of nanoemulsion containing aripiprazole. The optimum conditions suggested by the predicted model were: 120 min of overhead stirring time, 15 min of high shear homogenizer time, 4400 rpm of high shear homogenizer rate and 11 cycles of high-pressure homogenizer, giving a desirable droplet size of nanoemulsion containing aripiprazole of 64.52 nm for experimental value and 62.59 nm for predicted value. The analysis of variance (ANOVA) showed the quadratic polynomial fitted the experimental values with This proven that response surface methodology is an efficient tool to produce desirable droplet size of nanoemulsion containing aripiprazole for parenteral delivery application.
Sections du résumé
BACKGROUND
BACKGROUND
Aripiprazole, which is a quinolinone derivative, has been widely used to treat schizophrenia, major depressive disorder, and bipolar disorder.
PURPOSE
OBJECTIVE
A Central Composite Rotatable Design (CCRD) of Response Surface Methodology (RSM) was used purposely to optimize process parameters conditions for formulating nanoemulsion containing aripiprazole using high emulsification methods.
METHODS
METHODS
This design is used to investigate the influences of four independent variables (overhead stirring time (A), shear rate (B), shear time (C), and the cycle of high-pressure homogenizer (D)) on the response variable namely, a droplet size (Y) of nanoemulsion containing aripiprazole.
RESULTS
RESULTS
The optimum conditions suggested by the predicted model were: 120 min of overhead stirring time, 15 min of high shear homogenizer time, 4400 rpm of high shear homogenizer rate and 11 cycles of high-pressure homogenizer, giving a desirable droplet size of nanoemulsion containing aripiprazole of 64.52 nm for experimental value and 62.59 nm for predicted value. The analysis of variance (ANOVA) showed the quadratic polynomial fitted the experimental values with
CONCLUSION
CONCLUSIONS
This proven that response surface methodology is an efficient tool to produce desirable droplet size of nanoemulsion containing aripiprazole for parenteral delivery application.
Identifiants
pubmed: 32210553
doi: 10.2147/IJN.S198914
pii: 198914
pmc: PMC7069580
doi:
Substances chimiques
Emulsions
0
Aripiprazole
82VFR53I78
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1585-1594Informations de copyright
© 2020 Samiun et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Neurobiol Dis. 2010 Jan;37(1):13-25
pubmed: 19664713
BMC Neurol. 2017 Jan 31;17(1):20
pubmed: 28143595
J Control Release. 2008 Apr 21;127(2):97-109
pubmed: 18313785
Int J Nanomedicine. 2015 Oct 13;10:6469-76
pubmed: 26508853
Biometrics. 2006 Jun;62(2):323-31
pubmed: 16918896
Stroke. 1974 May-Jun;5(3):330-3
pubmed: 4836535
Expert Opin Drug Deliv. 2013 Jul;10(7):889-905
pubmed: 23550609
Clin Ther. 2010;32 Suppl 1:S3-20
pubmed: 20152550
Arch Gen Psychiatry. 2003 Jul;60(7):681-90
pubmed: 12860772
Acta Trop. 2015 Feb;142:57-63
pubmed: 25447831
Pharm Sci Technolo Today. 1999 Apr;4(2):134-143
pubmed: 10322370
Eur J Pharm Biopharm. 2005 May;60(1):91-8
pubmed: 15848061
Cochrane Database Syst Rev. 2008 Jul 16;(3):CD006617
pubmed: 18646161
Curr Pharm Des. 2010;16(5):488-501
pubmed: 19909227
Cell Mol Neurobiol. 2005 Feb;25(1):5-23
pubmed: 15962506
J Control Release. 2012 Dec 10;164(2):145-55
pubmed: 22609350
J Psychiatr Res. 2007 Dec;41(11):895-905
pubmed: 17631314
Schizophr Res. 2014 Aug;157(1-3):112-9
pubmed: 24994555
J Control Release. 2014 Oct 28;192:243-8
pubmed: 25107692
Chem Cent J. 2017 Mar 2;11:21
pubmed: 28293282
Talanta. 2008 Sep 15;76(5):965-77
pubmed: 18761143
Asian J Pharm Sci. 2017 Jan;12(1):21-27
pubmed: 32104310
J Clin Psychiatry. 2007 Jan;68(1):29-36
pubmed: 17284127
Eur J Pharm Biopharm. 2002 Mar;53(2):203-8
pubmed: 11880004
Ultrason Sonochem. 2016 Mar;29:299-308
pubmed: 26585010
Colloids Surf B Biointerfaces. 2013 Dec 1;112:113-9
pubmed: 23974000
Am J Psychiatry. 1991 Dec;148(12):1697-704
pubmed: 1957932
Expert Opin Investig Drugs. 2007 Jun;16(6):771-5
pubmed: 17501690
Cochrane Database Syst Rev. 2014 Jan 02;(1):CD006569
pubmed: 24385408
Med Devices (Auckl). 2015 Nov 11;8:473-84
pubmed: 26635489
Adv Colloid Interface Sci. 2010 Jan 15;153(1-2):30-42
pubmed: 19913777
J Pharm Sci. 2017 Feb;106(2):446-456
pubmed: 27889072